CSBio Co. Revenue and Competitors
Estimated Revenue & Valuation
- CSBio Co.'s estimated annual revenue is currently $14.4M per year.
- CSBio Co.'s estimated revenue per employee is $155,000
Employee Data
- CSBio Co. has 93 Employees.
- CSBio Co. grew their employee count by -3% last year.
CSBio Co.'s People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Sr. Director, Instrumentation | Reveal Email/Phone |
3 | Director Operations | Reveal Email/Phone |
4 | Finance Manager | Reveal Email/Phone |
5 | Senior Manager | Reveal Email/Phone |
6 | Owner | Reveal Email/Phone |
7 | Business Development and Project Manager | Reveal Email/Phone |
8 | IT Support Technician, Operations | Reveal Email/Phone |
9 | Chemical Technician | Reveal Email/Phone |
10 | R&D Chemist | Reveal Email/Phone |
CSBio Co. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.7M | 37 | 9% | N/A | N/A |
What Is CSBio Co.?
C S Bio is a biotechnology company that has focused on providing peptide synthesizers and custom peptides to the life sciences community for over 10 years. Our complete line of automated synthesizers can be found in laboraories from research organizations to manufacturing facilities worldwide.
keywords:N/AN/A
Total Funding
93
Number of Employees
$14.4M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CSBio Co. News
... over the last five years, as well as the company profiles of key players/manufacturers: Aspen Pharma; GSK; Hepatunn; Changlong Pharma; CSBIO; Kingfriend...
Company Competitiveness Analysis: Peptide Therapeutics Contract API ... CSBio. 7.3. Contract Peptide API Manufacturers Based in Europe.
Subsequently, a scale-free co-expression network based on the soft threshold ... (http://www.csbio.sjtu.edu.cn/bioinf/lncLocator/) [39, 40].
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.5M | 93 | 1% | $80.4M |
#2 | $13.6M | 94 | -30% | N/A |
#3 | $13.3M | 95 | 48% | $124M |
#4 | N/A | 96 | 50% | N/A |
#5 | $7.5M | 97 | 24% | $3M |